C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

Late last year, The Jewish Hospital-Mercy Health in Cincinnati received a first-place award in a multi-state competition for its efforts to reduce Clostridium difficile infections among inpatients.

Please provide your email address to receive an email when new articles are posted on . Clostridioides difficile infection presents a unique treatment paradox for clinicians: Antibiotics are often ...

New live bacterial product for stubborn superbug improves quality of life Microbiome therapeutic tackles C. diff, the most common health care-associated infectious agent in the US. Date: January 31, ...

In a phase-one human clinical trial, a pharmacist researcher has demonstrated that a new antibiotic, called Omadacycline, may be a promising tool in combating the superbug known as C diff which causes ...

Each year, about 500,000 people in the U.S. deal with gastrointestinal infections from Clostridioides difficile (C. diff), and more than 20,000 die from these infections. A new study performed in mice ...

Kevin Garey, University of Houston Robert L. Boblitt Endowed Professor of Drug Discovery at the UH College of Pharmacy, assessed the pharmacokinetics and gut microbiome effects of oral Omadacycline in ...